1-Imidazolelactic acid | 876-19-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-Imidazolelactic acid
• 英文别名: 2-hydroxy-3-imidazol-1-ylpropanoic acid
• CAS: 876-19-7
• 化学式: C₆H₈N₂O₃
• 分子量: 156.14
• InChiKey: JTYMXXCJQKGGFG-UHFFFAOYSA-N

物化性质

• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  75.4
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2933290090

文献信息

• [EN] SUBSTITUTED alpha -HYDROXY ACID CASPASE INHIBITORS AND THE USE THEREOF<br/>[FR] ACIDES alpha -HYDROXY SUBSTITUES INHIBITEURS DE CASPASES ET LEURS UTILISATIONS
  申请人：CYTOVIA INC

  公开号：WO2001016093A1

  公开（公告）日：2001-03-08

  The present invention is directed to novel substituted α-hydroxy acid thereof, represented by general Formula (I), where R1-R5, X and Z are defined herein. The present invention also relates to the discovery that compounds having Formula (I) are potent inhibitors of caspases and apoptotic cell death. Therefore, the inhibitors of this invention can retard or block cell death in a variety of clinical conditions in which the loss of cells, tissues or entire organs occurs.

  本发明涉及一种新的取代α-羟基酸及其衍生物，其通式表示为（I），其中R1-R5，X和Z的定义如本文所述。本发明还涉及到化合物具有公式（I），是半胱天冬酶和凋亡细胞死亡的有效抑制剂的发现。因此，本发明的抑制剂可以延缓或阻止在细胞、组织或整个器官丢失的多种临床情况中的细胞死亡。
• SUBSTITUTED $g(a)-HYDROXY ACID CASPASE INHIBITORS AND THE USE THEREOF
  申请人：Cytovia, Inc.

  公开号：EP1212295A1

  公开（公告）日：2002-06-12
• SUBSTITUTED ALPHA-HYDROXY ACID CASPASE INHIBITORS AND THE USE THEREOF
  申请人：Cytovia, Inc.

  公开号：EP1212295B1

  公开（公告）日：2008-10-01
• MEMBRANE ACTIVE MOLECULES
  申请人：Branequest, Inc.

  公开号：EP3615084A1

  公开（公告）日：2020-03-04
• SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME
  申请人：Nodthera Limited

  公开号：US20210087147A1

  公开（公告）日：2021-03-25

  The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as autoinflammatory and autoimmune diseases and cancers.